Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway
| Autor: | Vamsi K. Kolukula, Jason Catania, Adolf Graessmann, Michael J. Pishvaian, Christopher Albanese, Daniel L. Stoler, Chad D. Knights, Geetaram Sahu, Ricardo E. Perez, Maria Laura Avantaggiati, Vasily Ogryzko |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Programmed cell death
Physiology Clinical Biochemistry Mutant Biology medicine.disease_cause Article Mice chemistry.chemical_compound Cell Line Tumor medicine Animals Humans p300-CBP Transcription Factors Loss function Cell Proliferation Mutation Promoter DNA Cell Biology Chromatin chemistry PCAF Acetylation Cancer research Tumor Suppressor Protein p53 Colorectal Neoplasms Protein Binding |
| Zdroj: | Journal of Cellular Physiology. 225:394-405 |
| ISSN: | 0021-9541 |
| DOI: | 10.1002/jcp.22285 |
| Popis: | Tumor-derived mutant forms of p53 compromise its DNA binding, transcriptional, and growth regulatory activity in a manner that is dependent upon the cell-type and the type of mutation. Given the high frequency of p53 mutations in human tumors, reactivation of the p53 pathway has been widely proposed as beneficial for cancer therapy. In support of this possibility p53 mutants possess a certain degree of conformational flexibility that allows for re-induction of function by a number of structurally different artificial compounds or by short peptides. This raises the question of whether physiological pathways for p53 mutant reactivation also exist and can be exploited therapeutically. The activity of wild-type p53 is modulated by various acetyl-transferases and deacetylases, but whether acetylation influences signaling by p53 mutant is still unknown. Here, we show that the PCAF acetyl-transferase is down-regulated in tumors harboring p53 mutants, where its re-expression leads to p53 acetylation and to cell death. Furthermore, acetylation restores the DNA-binding ability of p53 mutants in vitro and expression of PCAF, or treatment with deacetylase inhibitors, promotes their binding to p53-regulated promoters and transcriptional activity in vivo. These data suggest that PCAF-mediated acetylation rescues activity of at least a set of p53 mutations. Therefore, we propose that dis-regulation of PCAF activity is a pre-requisite for p53 mutant loss of function and for the oncogenic potential acquired by neoplastic cells expressing these proteins. Our findings offer a new rationale for therapeutic targeting of PCAF activity in tumors harboring oncogenic versions of p53. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text